Lipid Oxidation

Lipid Oxidation

Lipid oxidation, also referred to as fatty acid oxidation or beta-oxidation, is the catabolic process through which fatty acid molecules are sequentially cleaved within mitochondria to generate acetyl-CoA, NADH, and FADH2. These products enter the citric acid cycle and the electron transport chain to produce ATP, the primary energy currency of the cell. The rate of lipid oxidation is regulated by hormonal signals, substrate availability, and the energy demands of the organism. In fasting states, lipid oxidation increases substantially as the body shifts from glucose to fat as its primary fuel source, a metabolic transition governed largely by declining insulin levels and rising glucagon concentrations.

Hepatic lipid oxidation is of particular clinical interest in the context of metabolic disease. When fatty acid uptake by the liver exceeds the capacity for oxidation or export via very-low-density lipoproteins, the excess is stored as triglycerides, leading to hepatic steatosis. Enhancing lipid oxidation within hepatocytes can therefore reduce intrahepatic fat content and improve liver health. Glucagon receptor signaling is a potent stimulator of hepatic lipid oxidation, activating key enzymes in the beta-oxidation pathway and promoting the mobilization of stored triglycerides for energy production.

Clinical Relevance to Retatrutide

Retatrutide’s inclusion of glucagon receptor agonism distinguishes it from dual-agonist therapies like tirzepatide and is hypothesized to drive meaningful increases in hepatic lipid oxidation. In phase 2 clinical trials, participants treated with retatrutide demonstrated substantial reductions in liver fat, with some individuals achieving near-complete resolution of hepatic steatosis. These findings are consistent with glucagon-mediated enhancement of lipid oxidation in the liver, suggesting that the glucagon component of retatrutide contributes a metabolic benefit beyond what is achieved by GLP-1 and GIP receptor activation alone.